Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

Biogen executives said the company is pursuing a return to growth by diversifying beyond its historical neurology focus, advancing a broader late-stage pipeline, and managing expenses. The update signals a strategic repositioning but provides no new financial targets, trial data, or quantified outlook.